All In Biotech

NDA 022015 · Bayer Healthcare LLC

Miralax

Polyethylene Glycol 3350 · Oral · Osmotic Laxative

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Oct 6, 2006

Approved uses

1

Original approval plus efficacy supplements

Registered trials

127

31 Phase 3, 9 recruiting

FAERS reports

91,485

35,712 serious, 5,768 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 4, 2026.

Use relieves occasional constipation (irregularity) generally produces a bowel movement in 1 to 3 days

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 6, 2006 Original approval · Type 8 - Partial Rx to OTC Switch ReviewLetter
2 products under this application
  • MIRALAX · POLYETHYLENE GLYCOL 3350 17GM/SCOOPFUL · FOR SOLUTION, ORAL · Over-the-counter
  • MIRALAX · POLYETHYLENE GLYCOL 3350 17GM/PACKET · FOR SOLUTION, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Polyethylene Glycol 3350" as an intervention, any sponsor and status, largest first.

All 127 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product use issue9,984
  • drug ineffective9,750
  • off label use9,082
  • diarrhoea6,906
  • nausea5,179
  • constipation5,028
  • fatigue4,494
  • product use in unapproved indication3,743
  • vomiting3,140
  • incorrect drug administration duration2,828
  • incorrect dose administered2,808
  • pain2,794

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004203
2005247
2006305
2007327
2008496
2009625
2010757
2011957
20122,208
20134,116
20144,034
20156,832
20168,844
20178,277
20187,659
20196,756
20206,680
20216,010
20225,617
20235,158
20245,054
20256,064
20264,258

Recalls

1 FDA enforcement reports for this application.

  • Jun 29, 2022 · Class II · Terminated

    CGMP Deviations: products were stored outside the drug label specifications.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 65 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.